Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 673.06M | 9.04M | 6.25M | 13.58M | 7.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 673.06M | 9.04M | 6.25M | 13.58M | 7.89M |
| Cost of Revenue | 79.26M | 87.65M | 84.14M | 83.02M | 86.12M |
| Gross Profit | 593.80M | -78.61M | -77.89M | -69.45M | -78.23M |
| SG&A Expenses | 34.35M | 15.59M | 14.61M | 13.65M | 13.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.61M | 103.25M | 98.75M | 96.67M | 99.28M |
| Operating Income | 559.45M | -94.20M | -92.50M | -83.10M | -91.39M |
| Income Before Tax | 563.41M | -89.81M | -87.17M | -78.22M | -86.42M |
| Income Tax Expenses | 13.61M | -271.00K | -- | 0.00 | -- |
| Earnings from Continuing Operations | 549.81M | -89.54M | -87.17M | -78.22M | -86.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 549.81M | -89.54M | -87.17M | -78.22M | -86.42M |
| EBIT | 559.45M | -94.20M | -92.50M | -83.10M | -91.39M |
| EBITDA | 561.59M | -91.95M | -90.30M | -81.58M | -89.36M |
| EPS Basic | 4.93 | -0.81 | -0.79 | -0.82 | -1.03 |
| Normalized Basic EPS | 3.16 | -0.51 | -0.50 | -0.51 | -0.64 |
| EPS Diluted | 4.73 | -0.81 | -0.79 | -0.82 | -1.03 |
| Normalized Diluted EPS | 3.03 | -0.51 | -0.50 | -0.51 | -0.64 |
| Average Basic Shares Outstanding | 111.56M | 111.08M | 110.07M | 95.09M | 84.16M |
| Average Diluted Shares Outstanding | 116.15M | 111.08M | 110.07M | 95.09M | 84.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |